善宁联合抗肿瘤药物对肺腺癌细胞株Spc-al生长影响的实验研究  

Inhibitory Effect of Sandostatin and Anticarcinogens on the Growth of Lung-adenocarcinoma Cell Spc-al strain in Vitro

作　　者：徐振武[1] 黄诚[1] 苏颖[1] 林华妹[1] 邹长炎[1] 

机构地区：[1]福建省肿瘤医院,福州350014

出　　处：《海峡药学》2011年第7期209-211,共3页Strait Pharmaceutical Journal

基　　金：福建省卫生厅青年科学基金资助

摘　　要：目的观察不同浓度生长抑素类似物善宁与数种抗肿瘤药物在体外对肺腺癌细胞株Spc-al生长的影响。方法用MTT法检测不同浓度善宁联合抗癌药物对肺腺癌细胞Spc-al抑瘤试验。结果善宁对肺腺癌Spc-al细胞作用效应与其不同浓度的药物剂量呈明显正相关(P=0.0001);不同浓度善宁与顺铂1.0μg.mL-1及羟基喜树碱1.0μg.mL-1联用时有统计学差异(P值分别为:0.001,0.046);结论在体外善宁可有效抑制肺癌细胞Spc-al生长。与顺铂和羟基喜树碱药物配伍有累积抗癌效应。OBJECTIVE To observed the inhibitory effects of somatostatin analogue sandostatin and anticarcinogens on the growth of lung carcinoma cells and observe the apoptosis of the cells in vitro. METHODS in vitro, sandostatin combined with various antitumor drugswere added in Spc-al cell, after 72hr, we observed the degree of growth inhibition of spc-al cells by MTT assay method. RESULTS Different dosages of sandostatin and its inhibitory to Spc-al cell in vitro showed positive correlation（P = 0. 0001）;A statistical different be surveyed in different dosages of sandostatin combined with anticancer drugs cisplatin 1.0μg·mL^-1 or hydroxycamptothecin 1.0μg·mL^-1. CONCLUSIONS Sandostatin can alone inhibit proliferation of lung carcinoma cell and have a additive effect when combined with antituomr drugs cisplatin（DDP） and hydroxycamptothecin（OPT）.

关 键 词：善宁 肺腺癌 抗癌药 

分 类 号：R969.4[医药卫生—药理学]